Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 691751 multiple rising doses in healthy males
NCT02148107Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- May 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BI 691751 in atherosclerosis (7 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Subjects With Drug-related Adverse Events up to 35 days. Started May 2014; status: terminated.
02
Drugs
BI 691751
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT02148107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02148107.